Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: Results of the phase II GEMIA protocol

Haematologica

Volumn 84, Issue 3, 1999, Pages 226-230

  Martino, Rodrigo ^a   Guardia, Ramón ^b   Altés, Albert ^a   Sureda, Anna ^a   Brunet, Salut ^a   Sierra, Jorge ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Acute myeloid leukemia; Salvage chemotherapy

Indexed keywords

CYTARABINE; ETOPOSIDE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE; COMBINED MODALITY THERAPY; CYTARABINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; NEUTROPENIA; REMISSION INDUCTION; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR STEM CELLS;

EID: 0032855475     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jones L, Newland AC. The management of relapsed and refractory acute myeloid leukaemia in adults. Leuk Lymphoma 1991; 4:93-8.
2. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage chemotherapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071-80.
3. Estey E. Treatment of refractory AML. Leukemia 1996; 10:932-6.
4. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol 1997; 40:S9-12.
5. Sierra J, Grañena A, Bosch F, et al. Mitoxantrone and intermediate-dose cytosine arabinoside for poor-risk acute leukemias: response to treatment and factors influencing outcome. Hematol Oncol 1992; 10:301-9.
6. Burke PJ, Karp JE, Geller RB, Vaughan WP. Cures of leukemia with aggressive postremission treatment: an update of timed sequential therapy (Ac-D-Ac). Leukemia 1989; 3:692-4.
7. Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. Blood 1991; 77:1894-900.
8. Mitus AJ, Miller KB, Schenkein DT, et al. Improved survival for patients with acute myelogenous leukemia. J Clin Oncol 1995; 13:560-9.
9. Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol 1995; 13:11-8.
10. Sierra J, Brunet S, Grañena A, et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. J Clin Oncol 1996; 14:1353-63.
11. Brunet S, Esteve J, Berlanga J, et al. Hematopoietic stem cell trasnplantation after intensive chemotherapy in patients with acute myeloblastic leukemia: ongoing results of a prospective multicentertrial [abstract]. Bone Marrow Transplant 1998; 21 (Suppl 1):S7.
12. Hiddemann W, Martin WR, Sauerland CM, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment with thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia 1990; 4:184-8.
13. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14.
14. Martino R, Brunet S, Sureda A, Mateu R, Altés A, Domingo-Albös A. Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol. Leuk Lymphoma 1993; 11:393-8.
15. Martino R, Brunet S, Sureda A, et al. Hematopoietic growth factor (G-CSF or GM-CSF) after salvage chemotherapy in refractory or relapsed adult de novo acute leukemia. Leuk Lymphoma 1996; 20:321-6.
16. Kern W, Schleyer E, Unterhalt M, Wörmann B, Büchner T, Hiddemann W. High antileukemic activity of sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) in refractory acute leukemias: results of a phase II study. Cancer 1997; 79:59-68.
17. Aglietta M, De Vincentiis A, Lanata L, et al. Peripheral blood stem cells in acute myeloid leukemia: biology and clinical implications. Haematologica 1996; 81:77-92.
18. Martino R, Bellido M, Brunet S, et al. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21:1023-7.
19. De La Serna J, Tomas JF, Solano C, et al. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia. Leuk Lymphoma 1997; 25:365-72.
20. Bassan R, Chiodini B, Zucchetti M, et al. Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. Haematologica 1998; 83:27-33.
21. Bassan R, Lerede T, Buelli M, et al. A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia. Haematologica 1998; 83:422-7.
22. Cortes JE, Katarjian HM, Estey EH, et al. Promising approaches in acute leukemia: novel and revisited strategies. In: Freireich EJ, Kantarjian HM, eds. Medical management of hematological malignant diseases. New York: Marcel Dekker AG; 1998. p. 507-37.